Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Amicus Therapeutics, Inc.'s quarterly P/E stands at 35.3x. EV/EBITDA has compressed 48.7% YoY to 18.7x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -79.83 | 35.30 | — | — | 47.77 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 8.39 | 3.62 | 2.85 | 5.01 | 4.70 | 5.75 | 5.95 | 8.08 | 9.05 | 8.69 | 9.73 | 9.36 | 9.74 |
| — | -37.1% | -52.0% | -38.0% | -48.0% | -33.8% | -38.9% | -13.7% | -7.1% | -6.0% | +0.2% | +7.9% | -0.6% | |
| P/B Ratio | 22.54 | 10.62 | 8.65 | 12.97 | 14.52 | 18.20 | 22.74 | 27.30 | 26.01 | 26.99 | 32.96 | 31.50 | 27.89 |
| — | -41.7% | -62.0% | -52.5% | -44.2% | -32.6% | -31.0% | -13.3% | -6.8% | +18.5% | +82.3% | +175.1% | +166.2% | |
| P/FCF | — | 17.34 | — | 83.18 | — | — | 34.89 | — | 603.08 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 139.52 | 18.67 | — | — | 42.29 | 36.35 | 47.35 | — | — | — | — | — | — |
| — | -48.7% | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 187.45 | 14.67 | — | — | 38.29 | 44.48 | 64.35 | — | — | — | — | — | — |
| — | -67.0% | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Amicus Therapeutics, Inc.'s operating margin was 20.3% in Q3 2025, up 26.4 pp QoQ and up 5.0 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 4.6% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 3.6% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 90.0% | 87.4% | 90.2% | 90.7% | 90.1% | 90.6% | 91.1% | 87.7% | 90.2% | 90.4% | 90.4% | 92.0% | 89.3% |
| — | -3.6% | -1.0% | +3.4% | -0.1% | +0.3% | +0.8% | -4.6% | +0.9% | +8.2% | +0.6% | +1.8% | -1.2% | |
| Operating Margin | 4.7% | 20.3% | -6.1% | -6.3% | 10.7% | 15.3% | 11.8% | -25.1% | -3.2% | -16.4% | -20.0% | -43.6% | -48.0% |
| — | +32.4% | -151.8% | +74.7% | +432.5% | +193.1% | +159.2% | +42.4% | +93.3% | +60.3% | +73.4% | +54.4% | +45.3% | |
| Net Margin | -10.6% | 10.2% | -15.8% | -17.3% | 9.8% | -4.8% | -12.4% | -43.9% | -29.4% | -20.8% | -45.7% | -61.4% | -63.4% |
| — | +315.3% | -27.4% | +60.5% | +133.5% | +77.2% | +72.9% | +28.5% | +53.6% | +48.8% | +40.6% | +43.4% | +37.4% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -31.7% | 8.0% | -12.3% | -11.2% | 7.9% | -4.3% | -11.9% | -33.3% | -23.1% | -17.6% | -40.4% | -46.9% | -43.7% |
| — | +284.2% | -2.9% | +66.4% | +134.3% | +75.5% | +70.5% | +29.0% | +47.2% | +19.0% | -33.8% | -50.2% | -79.5% | |
| ROA | -7.2% | 2.1% | -3.0% | -2.8% | 1.9% | -0.9% | -2.1% | -6.5% | -4.4% | -2.9% | -6.0% | -7.4% | -7.5% |
| — | +334.6% | -42.6% | +57.4% | +142.7% | +69.7% | +64.7% | +13.1% | +41.7% | +32.3% | +20.9% | +24.5% | +15.8% | |
| ROIC | 4.8% | 5.3% | -1.5% | -1.4% | 2.9% | 4.3% | 3.1% | -5.7% | -0.8% | -3.8% | -3.8% | -6.9% | -8.7% |
| — | +23.3% | -149.1% | +76.4% | +462.8% | +213.7% | +180.8% | +16.5% | +90.6% | +48.4% | +64.9% | +41.8% | +25.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Amicus Therapeutics, Inc.'s Debt/EBITDA ratio is 12.3x — elevated, raising questions about debt serviceability. The current ratio has weakened 5.3% YoY to 2.99x, tightening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.29 | 1.92 | 2.17 | 2.29 | 2.29 | 2.49 | 3.35 | 3.40 | 2.78 | 3.41 | 4.05 | 4.41 | 3.67 |
| — | -22.7% | -35.2% | -32.6% | -17.7% | -27.1% | -17.3% | -22.8% | -24.4% | +0.3% | +55.8% | +134.9% | +156.6% | |
| Debt / EBITDA | 13.27 | 12.25 | — | — | 24.63 | 18.66 | 25.89 | — | — | — | — | — | — |
| — | -34.3% | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.39 | 2.99 | 3.21 | 3.34 | 3.39 | 3.15 | 2.75 | 3.03 | 2.88 | 2.73 | 2.72 | 2.89 | 3.05 |
| — | -5.3% | +16.8% | +10.1% | +17.8% | +15.3% | +1.1% | +5.1% | -5.5% | -1.8% | -10.1% | -27.8% | -25.4% | |
| Quick Ratio | 2.60 | 2.09 | 2.29 | 2.47 | 2.60 | 2.42 | 2.26 | 2.61 | 2.52 | 2.40 | 2.40 | 2.69 | 2.88 |
| — | -13.7% | +1.0% | -5.1% | +2.8% | +1.0% | -5.5% | -3.2% | -12.3% | -11.3% | -17.3% | -29.4% | -26.3% | |
| Interest Coverage | 0.50 | 2.93 | -0.82 | -0.69 | 1.34 | 1.71 | 1.20 | -2.23 | -0.29 | -1.31 | -1.51 | -3.18 | -3.82 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonAmicus Therapeutics, Inc.'s current P/E is -79.8x. The average P/E over the last 2 quarters is 41.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Amicus Therapeutics, Inc.'s current operating margin is 4.7%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Amicus Therapeutics, Inc.'s business trajectory between earnings reports.